FUSN News and Press, Fusion Pharmaceuticals Inc.

Acquisition of Fusion Pharmaceuticals Completed Canada NewsWire HAMILTON , ON and BOSTON , June 4, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), a...

2024-05-31 18:06:40 ET More on AstraZeneca, Fusion Pharmaceuticals, etc. AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market Amgen wins ...

Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement Canada NewsWire HAMILTON , ON and BOSTON , May 31, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation ...

2024-05-29 16:54:54 ET More on Fusion Pharmaceuticals What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook Fusion Pharmaceuticals GAAP EPS of -$0.39 misses by $0.06 Ast...

Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca Canada NewsWire HAMILTON, ON and BOSTON , May 29, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiocon...

2024-05-19 14:00:55 ET More on pharma companies Novo Nordisk, J&J lead R&D rankings in big pharma: report Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors Johnson & Johnson: Buy This Bargain Before It's Gone ...

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer Canada NewsWire AlphaBreak is a Phase 2/3 registrational program for FPI-2265 in patients with metastati...

2024-05-07 07:41:07 ET More on Fusion Pharmaceuticals What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook Fusion Pharmaceuticals GAAP EPS of -$0.39 misses by $0.06 Ast...

Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates Canada NewsWire Presented interim data from TATCIST trial of FPI-2265 in mCRPC at the 2024 American Association for Cancer Research (AACR) Annual Meeting Si...

2024-05-06 09:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...